ARTICLE | Emerging Company Profile
Flagship’s Vesalius subdividing common diseases by genetic circuits
Led by former NCATS Director Christopher Austin, the company is eschewing animal models for a ‘human-based’ approach
March 3, 2022 2:39 AM UTC
Flagship Pioneering’s Vesalius believes it can tackle a broad range of common diseases by splitting them into subsets defined by genetic circuits, and by sticking with human data.
Like other Flagship companies, Vesalius Therapeutics Inc. is being launched with a high-powered management team, substantial funding, lofty goals — and scant details about how it plans to achieve its ambitions. The company was founded in 2019 and, until its launch on March 2, has been quiet about its strategy and aspirations...